RecruitingNot ApplicableNCT05688969
Mechanisms of Anabolic Osteoporosis Therapy
Sponsor
Massachusetts General Hospital
Enrollment
16 participants
Start Date
Jun 14, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
Eligibility
Sex: FEMALEMin Age: 45 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying early versus late biopsy for people with osteoporosis, postmenopausal. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 45 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERearly versus late biopsy
early (3-6 weeks) versus late (6-8 months) biopsy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05688969
Related Trials
Sequential Therapies After Osteoanabolic Treatment
NCT061647958 locations
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
NCT069381521 location
Combined Anabolic Therapy
NCT065581881 location
Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship
NCT072534931 location
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
NCT072426121 location